Download PDF
CC BY-NC-ND 4.0 · International Journal of Epilepsy 2016; 03(02): 091-094
DOI: 10.1016/j.ijep.2016.09.002
Review article
Thieme Medical and Scientific Publishers Private Ltd.

Drug repositioning

Man Mohan Mehndiratta
a   Department of Neurology, Janakpuri Super Specialty Hospital, Janakpuri, New Delhi 110058, India
,
Swati Anil Wadhai
b   Department of Pathology, Janakpuri Super Specialty Hospital, Janakpuri, New Delhi 110058, India
,
Brij Kishor Tyagi
c   Janakpuri Super Specialty Hospital, Janakpuri, New Delhi 110058, India
,
Natasha Singh Gulati
b   Department of Pathology, Janakpuri Super Specialty Hospital, Janakpuri, New Delhi 110058, India
,
Madhu Sinha
b   Department of Pathology, Janakpuri Super Specialty Hospital, Janakpuri, New Delhi 110058, India
› Author Affiliations
Further Information

Publication History

Received: 04 July 2016

Accepted: 06 September 2016

Publication Date:
06 May 2018 (online)

   Permissions and Reprints

Abstract

Rapid advances in pharmacotherapy and bioinformatics has led to the discovery and growing popularity of drug repositioning which includes re-investigating or recycling of existing drugs for new indications. There are innumerable advantages as well as challenges of drug repositioning. Since de-novo drug discovery takes plenty of time, effort and money, it has proved to a preferred alternative strategy for accelerated drug discovery. Moreover it is relatively inexpensive and carries minimal risk due to availability of previous pharmacological, safety and toxicology data. The strategies used are Known drug – new target/Drug focus/Drug-centric, Known target- new indication/Target focus/Target-centric and Disease focus/Disease-centric. Drug repositioning is a new breakthrough strategy to benefit patients by offering safer and effective treatment using shelved drugs.

Keywords

Drug repositioning - De-novo drug discovery - Pharmacotherapy
 

  • References

  • 1 Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3 2004; 673-683
    CrossrefPubMedGoogle Scholar
  • 2 Shim JS, Liu JO. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 10 (07) 2014; 654-663
    CrossrefPubMedGoogle Scholar
  • 3 Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 20 (08) 2015; 1027-1034
    CrossrefPubMedGoogle Scholar
  • 4 Landers P. Drug industry's big push into technology falls short. Wall Street J February 2004; A1
    PubMedGoogle Scholar
  • 5 Usdin S. Industry development: pipeline or flatline?. BioCentury. 1. 2002
    PubMedGoogle Scholar
  • 6 Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med 24 2010; 1519
    PubMedGoogle Scholar
  • 7 Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg 8 2011; 1317
    PubMedGoogle Scholar
  • 8 Corbett A, Williams G, Ballard C. Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals 6 2013; 1304-1321
    CrossrefPubMedGoogle Scholar
  • 9 Persidis A. The benefits of drug repositioning. Drug Discov World Spring 2011; 9-12
    PubMedGoogle Scholar
  • 10 Cutting Edge Information. Pharmaceutical Product Relaunch: Preserving Market Share through Line Extension and New Market Entry Strategies. 2007 April http://www.prnewswire.com/news-releases/drug-repurposing-the-most-affordable-relaunch-option-for-pharma-companies-58268372.html
    PubMedGoogle Scholar
  • 11 Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 57 2011; 153-160
    CrossrefPubMedGoogle Scholar
  • 12 Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 3 2004; 711-715
    CrossrefPubMedGoogle Scholar
  • 13 Braun MM, Farag-El-Massah S, Xu K, Cote TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 9 (07) 2010; 519-522
    CrossrefPubMedGoogle Scholar
  • 14 Jin G, Wong S. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19 (05) 2014; 637-644
    CrossrefPubMedGoogle Scholar
  • 15 Gupta S, Sung B, Prasad S, Webb L, Aggarwal B. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34 (09) 2013; 508-517
    CrossrefPubMedGoogle Scholar
  • 16 Li YY, Jones SJ. Drug repositioning for personalized medicine. Genome Med 4 (03) 2012; 27
    CrossrefPubMedGoogle Scholar
  • 17 Naylor S, Schonfeld JM. Therapeutic drug repurposing, repositioning and rescue. Part I. Overview. Drug Discov World Winter Ed 2015; 54-62
    PubMedGoogle Scholar
  • 18 Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?. Curr Treat Options Oncol 12 2011; 96-106
    CrossrefPubMedGoogle Scholar
  • 19 Blumenthal GM, Cortazar P, Zhang JJ. et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist 17 (08) 2012; 1108-1113
    CrossrefPubMedGoogle Scholar
  • 20 Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, St Jeor S. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 10 (06) 2009; 1069-1081
    CrossrefPubMedGoogle Scholar
  • 21 Caveney E, Caveney BJ, Somaratne R, Turner JR, Gourgiotis L. Pharmaceutical interventions for obesity: a public health perspective. Diabetes Obes Metab 13 (06) 2011; 490-497
    CrossrefPubMedGoogle Scholar
  • 22 Banach M, Piskorska B, Borowicz-Reutt KK. Propafenone enhances the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock model. Pharmacol Rep 68 June (3) 2016; 555-560
    CrossrefPubMedGoogle Scholar
  • 23 von Philipsborn G, Gries J, Hofmann HP. et al. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung 34 1984; 1489-1497
    PubMedGoogle Scholar
  • 24 Mori K, Ito H, Toda Y. et al. Successful management of intractable epilepsy with lidocaine tapes and continuous subcutaneous lidocaine infusion. Epilepsia 45 2004; 1287-1290
    CrossrefPubMedGoogle Scholar
  • 25 Enoki H, Hata H, Ohmori I, Maniwa S, Ohta H, Kobayashi K. Clinical applications and the effect of mexiletine on refractory epilepsies (Japanese). No To Hattatsu 32 2000; 29-34
    PubMedGoogle Scholar
  • 26 Miyamoto A, Takahashi S, Oki J. A successful treatment with intravenous lidocaine followed by oral mexiletine in a patient with Lennox–Gastaut syndrome (Japanese). No To Hattatsu 31 1999; 459-464
    PubMedGoogle Scholar
  • 27 Nakazawa M, Okumura A, Niijima S. et al. Oral mexiletine for lidocaine-responsive neonatal epilepsy. Brain Dev 35 2013; 667-669
    CrossrefPubMedGoogle Scholar
  • 28 Alexander GJ, Kopeloff LM, Alexander RB, Chatterjie N. Mexiletine: biphasic action on convulsive seizures in rodents. Neurobehav Toxicol Teratol 8 1986; 231-235
    PubMedGoogle Scholar
  • 29 de Oliveira GG, Borges MA. Propranolol action in chronically unstable generalized epilepsy. Am J Ther 1 1994; 38-41
    CrossrefPubMedGoogle Scholar
  • 30 Borowicz KK, Banach M. Antiarrhythmic drugs and epilepsy. Pharmacol Rep 66 2014; 545-551
    CrossrefPubMedGoogle Scholar
  • 31 Lathers CM, Stauffer AZ, Tumer N, Kraras CM, Goldman BD. Anticonvulsant and antiarrhythmic actions of the beta blocking agent timolol. Epilepsy Res 4 1989; 42-54
    CrossrefPubMedGoogle Scholar
  • 32 Ozbakis-Dengiz G, Bakirci A. Anticonvulsant and hypnotic effects of amiodarone. J Zhejiang Univ Sci B 10 2009; 317-322
    CrossrefPubMedGoogle Scholar
  • 33 Vezzani A, Wu HQ, Stasi MA, Angelico P, Samanin R. Effect of various calcium channel blockers on three different models of limbic seizures in rats. Neuropharmacology 27 1988; 451-458
    CrossrefPubMedGoogle Scholar
  • 34 Wurpel JN, Iyer SN. Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia 35 1994; 443-449
    CrossrefPubMedGoogle Scholar
  • 35 Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 46 2005; 967-969
    CrossrefPubMedGoogle Scholar
  • 36 Schmitt FC, Dehnicke C, Merschhemke M, Meencke HJ. Verapamil attenuates the malignant treatment course in recurrent status epilepticus. Epilepsy Behav 17 2010; 565-568
    CrossrefPubMedGoogle Scholar
  • 37 Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38 2004; 1631-1634
    CrossrefPubMedGoogle Scholar